
Ashley A Leech

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/859218/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness of Operating on Traumatic Spinal Injuries in Low-Middle Income Countries: A Preliminary Report From a Major East African Referral Center. Global Spine Journal, 2022, 12, 15-23.	2.3	12
2	Medicaid prevalence and opioid use disorder treatment access disparities. Health Services Research, 2022, 57, 422-429.	2.0	6
3	Modelling the potential cost-effectiveness of food-based programs to reduce malnutrition. Global Food Security, 2021, 29, 100550.	8.1	10
4	Author's Reply. Value in Health, 2021, 24, 1086-1087.	0.3	0
5	A Comparison of Methods to Identify Antenatal Substance Use Within Electronic Health Records. American Journal of Obstetrics & Gynecology MFM, 2021, , 100535.	2.6	0
6	Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. Value in Health, 2020, 23, 1292-1299.	0.3	9
7	HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. AIDS Patient Care and STDs, 2020, 34, 295-302.	2.5	5
8	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. PLoS ONE, 2020, 15, e0238375.	2.5	9
9	Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. JAMA Network Open, 2020, 3, e2013456.	5.9	84
10	Neonatal Abstinence Syndrome In The United States, 2004–16. Health Affairs, 2020, 39, 764-767.	5.2	44
11	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S Oncologist, 2020, 25, e1117-e1119.	3.7	5
12	Are low and middle-income countries prioritising high-value healthcare interventions?. BMJ Global Health, 2020, 5, e001850.	4.7	13
13	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0
14	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0
15	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0
16	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0
17	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0
18	Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.		0

ASHLEY A LEECH

#	Article	IF	CITATIONS
19	Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions. Pharmacoeconomics, 2019, 37, 597-608.	3.3	46
20	Cost-Effective But Unaffordable: The CAR-T Conundrum. Journal of the National Cancer Institute, 2019, 111, 644-645.	6.3	12
21	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health, 2018, 21, 759-761.	0.3	108
22	Assessing access to assisted reproductive services for serodiscordant couples with human immunodeficiency virus infection. Fertility and Sterility, 2018, 109, 473-477.	1.0	10
23	Cost-Effectiveness Thresholds: the Past, the Present and the Future. Pharmacoeconomics, 2018, 36, 509-522.	3.3	124
24	Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. Aids, 2018, 32, 2787-2798.	2.2	7
25	Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers. Journal of Health Disparities Research and Practice, 2018, 11, 19-33.	1.1	3
26	Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. AIDS Patient Care and STDs, 2017, 31, 348-355.	2.5	22